PMID- 24197584
OWN - NLM
STAT- MEDLINE
DCOM- 20140312
LR  - 20181202
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 71
IP  - 10
DP  - 2013
TI  - Impact of levosimendan on right ventricular functions by using novel tissue 
      Doppler derived indices in patients with ischaemic left ventricular failure.
PG  - 1036-41
LID - 10.5603/KP.2013.0258 [doi]
AB  - BACKGROUND: Right ventricular (RV) dysfunction complicates advanced left 
      ventricular (LV) heart failure (HF) and contributes to a poor prognosis. 
      Levosimendan is a positive inotropic agent improving cardiac contractility 
      without increasing myocardial oxygen consumption in HF. AIM: To evaluate the 
      effect of levosimendan therapy on RV systolic function, by using derived tissue 
      Doppler imaging (TDI) in patients with ischaemic HF. METHODS: The study consisted 
      of 30 patients with HF who were admitted to our hospital due to new onset of 
      decompensated HF, having LV ejection fraction < 40%, with functional status class 
      III-IV, according to the New York Heart Association (NYHA). TDI-derived systolic 
      velocities of tricuspid annulus (isovolumic myocardial acceleration [IVA], peak 
      myocardial velocity during isovolumic contraction [IVV], peak systolic velocity 
      during ejection period [Sa]) and diastolic indices (early [Ea] and late diastolic 
      [Aa] velocities, Ea/Aa, E/Ea ratios and myocardial performance index [Tei index]) 
      were measured. 72 hours after treatment, all measurements were re-evaluated. 
      RESULTS: Considering TDI-derived systolic indices of the RV, IVA and IVV 
      increased significantly, whereas Tei index decreased, after the therapy. Also, 
      there was a significant decrease in serum levels of B-type natriuretic peptide. 
      No significant change was observed in TDI derived diastolic indices of the RV. 
      CONCLUSIONS: Levosimendan improves RV systolic function as expressed by 
      TDI-derived parameters in patients with acutedecompensated HF.
FAU - Alibaz-Oner, Fatma
AU  - Alibaz-Oner F
AD  - Marmara University, School of Medicine. falibaz@gmail.com.
FAU - Gurbuz, Ozlem Zeynep
AU  - Gurbuz OZ
FAU - Oner, Ender
AU  - Oner E
FAU - Yurdakul, Selen
AU  - Yurdakul S
FAU - Erguney, Mecdi
AU  - Erguney M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Cardiotonic Agents/*pharmacology
MH  - Echocardiography, Doppler
MH  - Female
MH  - Heart Failure/complications/*diagnostic imaging/*drug therapy
MH  - Humans
MH  - Hydrazones/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Pyridazines/*pharmacology
MH  - Simendan
MH  - Ventricular Dysfunction, Right/complications/*diagnostic imaging/*drug therapy
EDAT- 2013/11/08 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/11/08 06:00
PHST- 2013/05/02 00:00 [received]
PHST- 2013/11/08 06:00 [entrez]
PHST- 2013/11/08 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - VM/OJS/KP/7311 [pii]
AID - 10.5603/KP.2013.0258 [doi]
PST - ppublish
SO  - Kardiol Pol. 2013;71(10):1036-41. doi: 10.5603/KP.2013.0258.